JP5765937B2 - 小児腫瘍の治療 - Google Patents
小児腫瘍の治療 Download PDFInfo
- Publication number
- JP5765937B2 JP5765937B2 JP2010518590A JP2010518590A JP5765937B2 JP 5765937 B2 JP5765937 B2 JP 5765937B2 JP 2010518590 A JP2010518590 A JP 2010518590A JP 2010518590 A JP2010518590 A JP 2010518590A JP 5765937 B2 JP5765937 B2 JP 5765937B2
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- treatment
- tumors
- childhood
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
の化合物の使用である。
様々な小児腫瘍異種移植モデルに対するin vivoの抗腫瘍活性
様々なヒト小児腫瘍モデルに対して抗腫瘍効果を評価した:SK-ND-AS(神経芽細胞腫)、PSFK(原始神経外胚葉性腫瘍/PNET)、TE-671(横紋筋肉腫)。ST1968を、スケジュールq4d×4に従って、ST1968に対して30mg/10ml/kg、及びCPT-11に対して50mg/10ml/kgの静脈内送達によって、CPT-11(イリノテカン)と比べて評価した。
指数関数的に増殖している腫瘍細胞を、胸腺欠損ヌードマウス中にs.c.注射した。腫瘍細胞の数を、増殖曲線によって予め選択した。マウスを、ステンレススチール製のカバーフィード付き、滅菌済み、ダストフリーのベディングコブ(bedding cob)を有するマクロロンケージ(33.2×15×13cm)中で飼育した。動物を、明暗サイクル下、温度及び湿度を一定に保って飼育した。動物室のパラメータは以下の通りに評価された:温度22±2℃、相対湿度55±10%、1時間あたり約15〜20回のろ過空気の交換、人工光線の12時間の概日サイクル(午前7時、午後7時)。依頼により環境条件をモニターした。データはAnimal Housing Archivesに保持する。飲料水を適宜供給した。各マウスには、試験を通して、毎日、完全ペレット食(GLP4RF21、Mucedola)を提供した。動物の餌及び水の分析証明書はSigma-Tau構内に保持してある。動物はすべて、実験開始前に体重測定し、様々な投与量群にさらに分けた。
in vivo試験において、ST1968は、CPT-11に比べて、全モデルにおいて完全な腫瘍の退行が好適な速度である、顕著な抗腫瘍活性を示した。最も印象的な抗腫瘍効果は、腫瘍体積の阻害(TWI)がそれぞれ99%または100%であるという、高率の完全な反応によって実証されるように、PNET及び横紋筋肉腫モデルに対して観察された(表1)。興味深いことに、ST1968治療は、概ね、マウスで良好な忍容性を示し、急性毒性または遅延毒性の徴候はなかった。
Claims (3)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07113603 | 2007-08-01 | ||
EP07113603.0 | 2007-08-01 | ||
PCT/EP2008/058601 WO2009015981A2 (en) | 2007-08-01 | 2008-07-03 | Treatment of pediatric tumors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014042649A Division JP2014111653A (ja) | 2007-08-01 | 2014-03-05 | 小児腫瘍の治療 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010534699A JP2010534699A (ja) | 2010-11-11 |
JP2010534699A5 JP2010534699A5 (ja) | 2011-08-04 |
JP5765937B2 true JP5765937B2 (ja) | 2015-08-19 |
Family
ID=38799381
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010518590A Expired - Fee Related JP5765937B2 (ja) | 2007-08-01 | 2008-07-03 | 小児腫瘍の治療 |
JP2014042649A Ceased JP2014111653A (ja) | 2007-08-01 | 2014-03-05 | 小児腫瘍の治療 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014042649A Ceased JP2014111653A (ja) | 2007-08-01 | 2014-03-05 | 小児腫瘍の治療 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8829021B2 (ja) |
EP (1) | EP2182951A2 (ja) |
JP (2) | JP5765937B2 (ja) |
KR (1) | KR20100051837A (ja) |
CN (1) | CN101784277A (ja) |
BR (1) | BRPI0815051A2 (ja) |
CA (1) | CA2694389C (ja) |
EA (1) | EA015933B1 (ja) |
MX (1) | MX2010001084A (ja) |
SG (1) | SG183010A1 (ja) |
WO (1) | WO2009015981A2 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2912193T (pt) | 2012-10-29 | 2018-11-29 | Arizona Board Of Regents On Behalf Of Univ Of Arizona | Marcadores preditivos para terapêuticas de cancro de inibidor de poliamina |
JP2017519770A (ja) | 2014-06-18 | 2017-07-20 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティ オブ アリゾナ | Odc1遺伝子型に基づく癌腫の診断および処置 |
JP2018507910A (ja) * | 2015-02-12 | 2018-03-22 | ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ジ・ユニバーシティ・オブ・アリゾナ | 神経芽細胞腫を治療する方法 |
CN108366982A (zh) | 2015-10-30 | 2018-08-03 | 癌症预防制药股份有限公司 | 依氟鸟氨酸和舒林酸,固定剂量的组合制剂 |
US10945981B2 (en) | 2019-05-17 | 2021-03-16 | Cancer Prevention Pharmaceuticals, Inc. | Methods for treating familial adenomatous polyposis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE216998T1 (de) * | 1999-03-09 | 2002-05-15 | Sigma Tau Ind Farmaceuti | Camptothecin-derivate mit antitumor-wirkung |
PL1962850T3 (pl) * | 2005-12-21 | 2012-07-31 | Sigma Tau Ind Farmaceuti | Leczenie lekoopornych nowotworów |
EP2120948A1 (en) * | 2007-02-13 | 2009-11-25 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives |
-
2008
- 2008-07-03 CN CN200880101385A patent/CN101784277A/zh active Pending
- 2008-07-03 BR BRPI0815051-6A2A patent/BRPI0815051A2/pt not_active IP Right Cessation
- 2008-07-03 JP JP2010518590A patent/JP5765937B2/ja not_active Expired - Fee Related
- 2008-07-03 EP EP08774713A patent/EP2182951A2/en not_active Withdrawn
- 2008-07-03 WO PCT/EP2008/058601 patent/WO2009015981A2/en active Application Filing
- 2008-07-03 MX MX2010001084A patent/MX2010001084A/es active IP Right Grant
- 2008-07-03 US US12/669,134 patent/US8829021B2/en not_active Expired - Fee Related
- 2008-07-03 SG SG2012050597A patent/SG183010A1/en unknown
- 2008-07-03 EA EA201070193A patent/EA015933B1/ru not_active IP Right Cessation
- 2008-07-03 KR KR1020107004521A patent/KR20100051837A/ko not_active Application Discontinuation
- 2008-07-03 CA CA2694389A patent/CA2694389C/en not_active Expired - Fee Related
-
2014
- 2014-03-05 JP JP2014042649A patent/JP2014111653A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
JP2010534699A (ja) | 2010-11-11 |
CA2694389C (en) | 2016-01-19 |
US20100197718A1 (en) | 2010-08-05 |
CN101784277A (zh) | 2010-07-21 |
AU2008282024A1 (en) | 2009-02-05 |
WO2009015981A2 (en) | 2009-02-05 |
SG183010A1 (en) | 2012-08-30 |
US8829021B2 (en) | 2014-09-09 |
BRPI0815051A2 (pt) | 2015-02-10 |
EA015933B1 (ru) | 2011-12-30 |
KR20100051837A (ko) | 2010-05-18 |
CA2694389A1 (en) | 2009-02-05 |
EP2182951A2 (en) | 2010-05-12 |
JP2014111653A (ja) | 2014-06-19 |
MX2010001084A (es) | 2010-03-25 |
WO2009015981A3 (en) | 2009-09-03 |
EA201070193A1 (ru) | 2010-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | A core–shell structure QRu-PLGA-RES-DS NP nanocomposite with photothermal response-induced M2 macrophage polarization for rheumatoid arthritis therapy | |
CN104363913B (zh) | Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途 | |
US8481553B2 (en) | Antimetastatic compounds | |
US20150087687A1 (en) | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | |
WO2004080462A1 (ja) | c-Kitキナーゼ阻害剤 | |
JP2018515569A (ja) | キナーゼを調節するための化合物の固体形態 | |
JP2014111653A (ja) | 小児腫瘍の治療 | |
CN110981870B (zh) | 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途 | |
JP6570042B2 (ja) | 官能化ベンゾピラン化合物およびその使用 | |
JP2005508856A (ja) | 血管形成を阻害する方法 | |
WO2019126739A1 (en) | Pyrvinium pamoate anti-cancer therapies | |
KR20210006365A (ko) | 구동 종양원성 돌연변이를 갖는 암의 치료 | |
WO2019109074A1 (en) | Mebendazole cancer therapies and methods of use | |
TW202128174A (zh) | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 | |
Fan et al. | Design, synthesis and biological evaluation of N-anthraniloyl tryptamine derivatives as pleiotropic molecules for the therapy of malignant glioma | |
AU2008282024B2 (en) | Treatment of pediatric tumors | |
US20230277522A9 (en) | Methods for treating vascular malformations | |
ES2935705T3 (es) | Un ligando del receptor GABA A | |
US20210137898A1 (en) | Methods to treat gliomas using a stat3 inhibitor | |
CN102633668B (zh) | 化合物在转录因子失调相关疾病的治疗药物中的应用 | |
US8853233B2 (en) | Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives | |
Zhang et al. | Metformin-Loaded into Chitosan Hydrogel Suppresses Bladder Tumour Growth in an Orthotopic Mouse Model via Intravesical Administration | |
EP4013417A1 (en) | Methods and compositions for treating vascular malformations | |
CN117999076A (zh) | 一类1, 4-二氢-萘啶衍生物在治疗肿瘤中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110617 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130312 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130603 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130625 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130925 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131105 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140305 |
|
A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140320 |
|
A912 | Removal of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140523 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150616 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5765937 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |